Browse the evidence

Bariatric surgery is recommended for eligible patients with noncirrhotic MASLD to achieve sustained weight reduction and remission of type 2 diabetes.

If you have severe obesity and MASLD, discuss bariatric surgery with your doctor. It can lead to significant weight loss and remission of type 2 diabetes, reducing your risk of liver and heart disease.

Prevention of GLP-1RA-induced muscle loss requires a multimodal strategy combining resistance exercise, high protein intake (1.2-1.6 g/kg/day), and potentially specific supplements (BCAA, Creatine, Vitamin D).

To keep your muscles while losing weight on GLP-1s, lift weights 2-3 times a week and eat 1.2-1.6 grams of protein per kg of your body weight every day. Spread this protein across 3 meals. Consider adding creatine or Vitamin D if your diet is lacking.

Combining GLP-1 receptor agonists with resistance and aerobic exercise training yields greater fat loss and better preservation of lean muscle mass compared to GLP-1 use alone.

If you are prescribed a GLP-1 medication for weight loss, do not rely on the drug alone. You must combine it with resistance and aerobic exercise. This combination is critical to ensure you lose fat rather than muscle, preserving your metabolic health and physical function.

A daily protein intake of approximately 1.6 grams per kilogram of body weight is recommended to spare lean body mass during weight loss induced by GLP-1 medications.

When losing weight on GLP-1s, aim to eat approximately 1.6 grams of protein for every kilogram of your body weight each day. This specific target helps protect your muscle mass from being lost along with the fat.

In individuals with Type 2 Diabetes Mellitus, a 15-minute post-meal walk at ~60% VO2peak significantly reduces daily insulin exposure (AUC) and post-prandial glucose/insulin spikes, whereas an 8-hour time-restricted eating (TRE) window alone does not significantly alter total daily blood glucose compared to a 12-hour window.

If you have Type 2 Diabetes, focus on taking a 15-minute walk after your main meals rather than strictly restricting your eating window to 8 hours for immediate glucose control. This specific timing of light-to-moderate intensity walking significantly lowers insulin requirements and reduces post-meal blood sugar spikes, which helps manage daily glycemic variability.

Combining GLP-1 receptor agonists with resistance training and/or specific nutritional strategies (e.g., higher protein, ketogenic therapy) preserves fat-free mass and muscle strength better than pharmacotherapy alone.

To prevent muscle loss while on GLP-1s, consider combining your medication with resistance training and a diet that supports muscle retention, such as one higher in protein or potentially ketogenic, under medical supervision.

Obesity medications (OMs) such as semaglutide and tirzepatide cause significant weight loss but also result in lean mass loss, necessitating targeted nutritional and exercise interventions to preserve skeletal muscle.

OMs like semaglutide and tirzepatide are highly effective for weight loss but can cause muscle loss. To counter this, eat enough protein (0.8-1.5 g/kg/day depending on your age/health) and do resistance exercises. This helps protect your muscle while you lose fat.

In a comprehensive digital obesity service using Tirzepatide, consistent weekly behavioral engagement (weight tracking and health coach communication) is the strongest predictor of 12-month adherence and weight loss, whereas hyper-engagement (intensive tracking frequency and high initial weight loss velocity) in the first month significantly increases the risk of program attrition.

To maximize your chances of long-term success with Tirzepatide in a digital program, prioritize consistent, moderate engagement over intense, rapid efforts. Track your weight weekly and communicate regularly with your health coach. Avoid the trap of 'hyper-engagement'—such as tracking daily or expecting massive weight loss in the first month—as this is strongly linked to dropping out of the program. Sustainable habits beat short bursts of intensity.

A 3-month intervention combining alternate day fasting (600 kcal on fast days) and moderate-intensity aerobic exercise significantly reduces intrahepatic triglyceride content and associated cardiometabolic risk in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).

For patients with fatty liver disease, a 3-month program of Alternate Day Fasting (eating 600 calories on fast days, normal on others) combined with 5 weekly sessions of moderate exercise (like brisk walking or cycling) significantly reduces liver fat. This approach is a validated, mainstay therapy that works by creating a caloric deficit and improving metabolic markers, even without drastic daily calorie counting.

High-intensity behavioral interventions involving at least 14 sessions over six months produce significant weight loss (5-10%) and improve glycemic control.

Structured behavioral programs are highly effective for weight loss, especially for those with type 2 diabetes. Committing to at least 14 sessions over six months can lead to a 5-10% reduction in body weight. These programs use techniques like self-monitoring and goal setting to improve adherence and health outcomes.

Semaglutide demonstrates the greatest mean reduction in body weight among GLP-1RAs in psychiatric populations, significantly outperforming placebo and showing superior efficacy to liraglutide and exenatide in network meta-analysis.

Among GLP-1 medications, semaglutide (oral) appears to produce the most significant weight loss in patients with psychiatric conditions, averaging over 6 kg (13 lbs) loss. It is more effective than liraglutide or exenatide in this group. However, data is limited to one study, so discuss availability and cost with your provider.

Dual GLP-1R/GIPR agonists (e.g., tirzepatide) provide superior glycemic control and weight reduction compared to single-target incretin agonists.

If you have type 2 diabetes or obesity, dual-acting medications like tirzepatide may offer better weight loss and blood sugar control than older single-acting drugs. These are injectable medications that mimic gut hormones to reduce appetite and improve insulin function. Consult a doctor to see if this advanced therapy is appropriate for your specific health profile.

Protein supplementation combined with resistance training is the most prominent and effective intervention strategy for promoting muscle hypertrophy.

To maximize muscle growth, combine regular resistance training with adequate protein intake. This combination is the most widely supported strategy in current research. Ensure your training is progressive, as protein alone is not enough to overcome adaptation plateaus.

Collagen supplementation significantly enhances fat-free mass and muscle strength gains in healthy adults undergoing resistance training, outperforming whey protein and other protein sources.

If you are doing resistance training, adding collagen supplements can significantly boost your muscle mass and strength gains, potentially more than whey protein. You don't need to rely solely on high-BCAA proteins; collagen's unique amino acids support muscle structure and recovery. Aim for a daily dose that fits your diet, as the study shows benefits across various dosages.

Whey protein supplementation significantly enhances muscle strength and fat-free mass gains compared to placebo, but is less effective than collagen.

Whey protein works for building muscle and strength, but the gains are smaller than those from collagen. If you are using whey, consider adding collagen to your regimen for potentially better results. Don't rely on whey alone if you want to maximize your strength and mass gains.

Replacing processed animal meats with plant-based meat analogues (PBMAs) significantly reduces saturated fat and total energy intake while increasing dietary fiber, leading to more favorable Nutri-Score ratings in most categories.

Switching from processed animal meats (like sausages and bacon) to plant-based analogues generally lowers your saturated fat and calorie intake while boosting fiber. However, check the label: many analogues are high in salt and sugar, and few are fortified with B12 or Iron. Choose products with lower sodium and consider a B12 supplement if you rely heavily on these substitutes.

GLP-1 receptor agonists (semaglutide, tirzepatide) produce clinically significant weight loss (15-21%) and improve comorbidities, but require long-term continuous use to maintain benefits.

GLP-1 medications like semaglutide and tirzepatide are highly effective for significant weight loss (15-21%) and improving health conditions like diabetes and heart disease. However, they are not cosmetic shortcuts. You must commit to long-term use, as stopping the medication usually leads to regaining the weight. Work with your doctor to manage side effects and adjust other medications as you lose weight.

GLP-1/GIP dual receptor agonists (e.g., tirzepatide) produce significantly greater weight loss than GLP-1 receptor agonists (e.g., semaglutide, liraglutide) and non-GLP-1 agents (e.g., orlistat, phentermine/topiramate) in weight management trials.

If you are struggling with obesity, GLP-1/GIP dual agonists like tirzepatide are currently the most effective pharmacological option for weight loss, significantly outperforming older medications and even single-target GLP-1 agonists. This comes with the need for weekly injections (or oral alternatives) and careful dose escalation to manage side effects.

GLP-1 receptor agonists (semaglutide 2.4 mg weekly) and dual incretin agonists (tirzepatide) significantly reduce hepatic steatosis and improve or resolve steatohepatitis (MASH) in patients with MASLD, primarily through sustained weight loss and improved insulin sensitivity.

If you have fatty liver disease linked to metabolic issues, GLP-1 medications like semaglutide are currently the most effective pharmacological tool to reverse liver inflammation and fat. They work by targeting the root metabolic causes rather than just the liver itself. Consult a doctor to see if you qualify for these treatments, especially if lifestyle changes alone haven't resolved your liver health markers.

Intensive lifestyle interventions (dietary restriction and exercise) can induce type 2 diabetes remission, with remission rates strongly dose-dependent on the magnitude of weight loss, particularly when exceeding 15 kg.

To achieve type 2 diabetes remission, you must lose a significant amount of weight, ideally 15 kg or more, through a combination of calorie-restricted diet and regular exercise (at least 150 minutes/week). This is not just about weight loss; it requires a multidisciplinary support system including dietitians and psychological counseling to manage the mental burden of strict lifestyle changes. Shorter diabetes duration and higher BMI (27-45) predict better success.

Tirzepatide, a dual GLP-1/GIP receptor agonist, provides greater HbA1c reduction and weight loss compared to semaglutide 1 mg in patients with Type 2 Diabetes.

If you need significant weight loss and blood sugar control, ask your doctor about tirzepatide. It may work better than older GLP-1 drugs like semaglutide 1 mg, but it is more expensive.

GLP-1 receptor agonists (semaglutide, tirzepatide) produce significant weight loss (10-21%) but also reduce lean body mass, necessitating resistance training to preserve muscle and performance in physically active individuals.

If you are using GLP-1 agonists like semaglutide or tirzepatide for weight loss, expect to lose both fat and some muscle. To protect your strength and athletic performance, you must incorporate resistance training into your routine. This combination helps offset the lean mass loss associated with these drugs. Do not rely on the medication alone; long-term maintenance requires continuous therapy and lifestyle adherence, as stopping treatment typically leads to weight regain.

Semaglutide (2.4 mg) is the most cost-effective and clinically effective pharmacological intervention for obesity treatment compared to other FDA-approved medications and lifestyle interventions.

For adults with obesity, Semaglutide (2.4 mg weekly) combined with diet and exercise is currently the most effective and economically favorable medication option available, outperforming older drugs like Orlistat in most healthcare settings.

Multidisciplinary therapy combining nutritional, physical, and behavioral interventions reduces body weight, fat mass, and cardiometabolic risk factors in adults with obesity.

To manage obesity effectively, you need a team approach that includes diet, exercise, and behavioral counseling, rather than just one of these. Aim for sessions 2-3 times a week, lasting at least 20 minutes, over a period of weeks to months. This combined approach helps reduce weight and fat while preserving muscle and improving metabolic health, which is crucial for long-term success.